Will Novartis continue business in India? Global Drug major strategic review to decide Ruchika Sharma17 Feb 2024 2:16 PM ISTDrug major Novartis AG has announced a strategic review of Novartis India Ltd, a public company listed on the BSE.The strategic review will include an...
CDSCO Panel Approves Novartis Protocol Amendment Proposal For Multiple Sclerosis Drug Ofatumumab Dr. Divya Colin11 Feb 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis to acquire MorphoSys AG for EUR 68 per share or aggregate of EUR 2.7bn in cash Ruchika Sharma6 Feb 2024 12:30 PM ISTBasel: Novartis has announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a...
CDSCO Panel grants Novartis Protocol Amendment proposal for Remibrutinib study in Relapsing Multiple Sclerosis Dr. Divya Colin5 Feb 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis Gets CDSCO Panel Nod to Study XXB750 in Patients With Heart Failure Dr. Divya Colin2 Feb 2024 6:00 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel Grants Novartis Protocol Amendment Proposal For anti-cholesterol drug Inclisiran Dr. Divya Colin28 Jan 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
EU regulator starts safety review of CAR-T cancer cell therapies Ruchika Sharma15 Jan 2024 9:00 AM ISTThe European Union's drug watchdog has said it had started a review into the safety risks associated with cancer cell therapies made by companies such...
Novartis Gets CDSCO Panel nod to study antimalarial drug KLU156 with Coartem Dr. Divya Colin14 Jan 2024 6:00 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis drops pursuit of Cytokinetics: Source Ruchika Sharma12 Jan 2024 4:00 PM ISTBasel: Swiss drugmaker Novartis has backed away from its pursuit of Cytokinetics, a person familiar with the matter told Reuters, and the...
Isomorphic Labs inks multi-target research collaboration with Novartis Ruchika Sharma12 Jan 2024 10:00 AM ISTLondon: Isomorphic Labs, a digital biology company has announced that it has entered into a strategic research collaboration with Novartis to...
Novartis in advanced talks to buy Cytokinetics: Source Ruchika Sharma10 Jan 2024 3:30 PM ISTAccess to Cytokinetics products would help Novartis offset the expected loss of U.S. exclusivity of Entresto, its key drug in this field, said...
CDSCO Panel Grants Novartis Protocol Amendment Proposal For Alpelisib Dr. Divya Colin7 Jan 2024 5:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
